These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22433968)

  • 1. Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test.
    Wilson S; Damery S; Stocken DD; Dowswell G; Holder R; Ward ST; Redman V; Wakelam MJ; James J; Hobbs FD; Ismail T
    Br J Cancer; 2012 Apr; 106(8):1431-8. PubMed ID: 22433968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma matrix metalloproteinase 9 as an early surrogate biomarker of advanced colorectal neoplasia.
    Gimeno-García AZ; Triñanes J; Quintero E; Salido E; Nicolás-Pérez D; Adrián-de-Ganzo Z; Alarcón-Fernández O; Abrante B; Romero R; Carrillo M; Ramos L; Alonso I; Ortega J; Jiménez A
    Gastroenterol Hepatol; 2016; 39(7):433-41. PubMed ID: 26601990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer.
    Damery S; Nichols L; Holder R; Ward ST; Warmington S; Wilson S; Wakelam MJ; James J; Ismail T
    Br J Cancer; 2013 Mar; 108(5):1149-56. PubMed ID: 23392084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing the added benefit of measuring MMP9 in FOB positive patients as a part of the Wolverhampton colorectal cancer screening programme.
    Wilson S; Taskila T; Ismail T; Stocken DD; Martin A; Redman V; Wakelam M; Perry I; Hobbs R
    BMC Cancer; 2009 Jan; 9():36. PubMed ID: 19175925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population.
    Wilson S; Wakelam MJ; Hobbs RF; Ryan AV; Dunn JA; Redman VD; Patrick F; Colbourne L; Martin A; Ismail T
    BMC Cancer; 2006 Oct; 6():258. PubMed ID: 17076885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients.
    Hurst NG; Stocken DD; Wilson S; Keh C; Wakelam MJ; Ismail T
    Br J Cancer; 2007 Oct; 97(7):971-7. PubMed ID: 17912241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening.
    Otero-Estévez O; De Chiara L; Rodríguez-Girondo M; Rodríguez-Berrocal FJ; Cubiella J; Castro I; Hernández V; Martínez-Zorzano VS
    Sci Rep; 2015 Aug; 5():13030. PubMed ID: 26264519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum matrix metalloproteinase-9 level as a biomarker for colorectal cancer: a diagnostic meta-analysis.
    Liang S; Chang L
    Biomark Med; 2018 Apr; 12(4):393-402. PubMed ID: 29575908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy.
    Collins MG; Teo E; Cole SR; Chan CY; McDonald SP; Russ GR; Young GP; Bampton PA; Coates PT
    BMJ; 2012 Jul; 345():e4657. PubMed ID: 22833618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer.
    Otero-Estévez O; De Chiara L; Barcia-Castro L; Páez de la Cadena M; Rodríguez-Berrocal FJ; Cubiella J; Hernández V; Martínez-Zorzano VS
    Sci Rep; 2016 May; 6():26703. PubMed ID: 27222072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological fecal occult blood test vs. serum ferritin for detection of colorectal neoplasia in high risk asymptomatic population.
    Sobrino-Cossío S; Fenocchi E; Hernández-Guerrero A; Alonso-Lárraga JO; De la Mora-Levy JG; Larracilla-Salazar I
    Rev Gastroenterol Mex; 2011; 76(3):191-8. PubMed ID: 22041307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum matrix metalloproteinase-9 is a valuable biomarker for identification of abdominal and thoracic aortic aneurysm: a case-control study.
    Li T; Jiang B; Li X; Sun HY; Li XT; Jing JJ; Yang J
    BMC Cardiovasc Disord; 2018 Oct; 18(1):202. PubMed ID: 30373522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial: Flexible sigmoidoscopy as an adjunct to faecal occult blood testing in population screening.
    Steele RJ; Carey FA; Stanners G; Lang J; Brand J; Brownlee LA; Crichton EM; Winter JW; Phull PS; Mowat C; Strachan JA; Digan AM; Fraser CG
    J Med Screen; 2020 Jun; 27(2):59-67. PubMed ID: 31690179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia.
    Haug U; Kuntz KM; Knudsen AB; Hundt S; Brenner H
    Br J Cancer; 2011 May; 104(11):1779-85. PubMed ID: 21559011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort.
    Chen LS; Yen AM; Chiu SY; Liao CS; Chen HH
    Lancet Oncol; 2011 Jun; 12(6):551-8. PubMed ID: 21592859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
    Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
    Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening.
    Parra-Blanco A; Gimeno-García AZ; Quintero E; Nicolás D; Moreno SG; Jiménez A; Hernández-Guerra M; Carrillo-Palau M; Eishi Y; López-Bastida J
    J Gastroenterol; 2010 Jul; 45(7):703-12. PubMed ID: 20157748
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.